Skip to main content
. 2024 Aug 30;89:102019. doi: 10.1016/j.molmet.2024.102019

Figure 3.

Figure 3

Effect of semaglutide on activated microglia (IBA1+) and reactive astroglia (GFAP+) in 12-month-old 5XFAD and APP/PS1 mice. Representative images of IBA1+ cells (green), GFAP+ cells (red), or cells co-stained with both IBA1 and GFAP antibodies (bottom panel) in the hippocampus (Hippo) or subiculum (Sub) of 12-month-old WT and vehicle- or semaglutide (25 nmol/kg)-treated 5XFAD (A) and APP/PS1 (B) mice. Scale bars represent 300 μm. Areas of interest are encircled by dashed lines. (C–J) Quantification of the number of IBA1+ cells per area (C, D) and the number of GFAP+ cells per area (E, F) in the hippocampus of 12-month-old female (♀) and male (♂) WT and 5XFAD mice. Quantification of the number of IBA1+ cells per area (G, H) and the number of GFAP+ cells per area (I, J) in the hippocampus of 12-month-old female (♀) and male (♂) WT and APP/PS1 mice. Data (C–J) were analyzed by 1-way ANOVA with Tukey's post-hoc test. #p < 0.05, ##p < 0.01 ###p < 0.001, ####p < 0.0001 WT vs. transgenic mice. Data are represented as means ± SD. n = 4–8 in each group of vehicle (Veh)- or semaglutide (Sema)-treated mice.